Efficacy and safety of remazolam and propofol in hepatic radiofrequency ablation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078192

Enrollment

Unknown

Registered

2023-11-30

Start date

2023-12-01

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatoma

Interventions

Control group:Propofol is used for induction and maintenance of anesthesia

Intervention group:Remazolam is used for induction and maintenance of anesthesia

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA grades 1-3, age 30-60 years, body mass index (BMI) <30kg m-2, 60 patients undergoing ultrasound-guided percutaneous radiofrequency ablation for liver cancer in the Affiliated Hospital of North Sichuan Medical College.

Exclusion criteria

Exclusion criteria: Patients with a history of hypertension, coronary heart disease, diabetes, central nervous system diseases, patients with poor cardiopulmonary function, and patients with contraindications in the use of propofol or remazolam.

Design outcomes

Primary

Measure	Time frame
Heart rate;Mean arterial blood pressure;Respiratory rate;modified observer's assessment of alert / sedation, MOAA/S;Partial pressure of end-expiratory carbon dioxide;	—

Secondary

Measure	Time frame
Visual analogue pain score,VAS;Duration of anesthesia;Duration of hepatic radiofrequency ablation;Recovery time;The dose of analgesic drugs;	—

Countries

China

Contacts

Public ContactJiang Pingping

Affiliated Hospital of North Sichuan Medical College

307174907@qq.com+86 158 8149 6034

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026